Deutsche Bank Raises Acadia Pharmaceuticals (NASDAQ: ACAD) Price Target on DAYBU Approval Hopes

• Analyst David Hoang of Deutsche Bank has raised the price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $37.00, citing positive developments.
• The European Medicines Agency (CHMP) has recommended the approval of Acadia Pharmaceuticals' drug, DAYBU, for Rett syndrome, marking a significant turnaround.
• The market responded strongly to the news, with Acadia Pharmaceuticals' shares jumping over 10 percent and the company maintaining a market capitalization of approximately $4.31 billion.

Analyst David Hoang of Deutsche Bank raises the price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $37.00 from a previous target of $32.00. Acadia Pharmaceuticals is a biopharmaceutical company that develops treatments for central nervous system disorders. Based on the stock's price of $25.06 at the time, the new target represents a potential upside of 47.67%.

This analyst upgrade is supported by recent positive news from Europe. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) now recommends the approval of Acadia Pharmaceuticals' drug, DAYBU. This drug is designed to treat the neurobehavioral symptoms of Rett syndrome, a rare neurological condition.

The recommendation marks a significant turnaround. As highlighted by Investor's Business Daily, the CHMP had previously voted against the drug in February. The new positive opinion is based on data from a Phase 3 study that showed significant improvements in patients. If final approval is granted, DAYBU will become the first authorized treatment for Rett syndrome in the European Union.

The market reacted strongly to the news, with shares of Acadia Pharmaceuticals jumping more than 10 percent. The stock is currently trading around $25.19, with a 52-week range between $19.69 and $28.35. The company has a market capitalization, which is the total value of all its shares, of approximately $4.31 billion.

According to RBC Capital Markets analyst Brian Abrahams, regulators may have previously had concerns about the drug's effectiveness and side effects. The CHMP's re-examination and positive recommendation suggest these issues have been sufficiently addressed, leading to renewed confidence from the market and analysts.